Interventional Glaucoma

Dr. Tanna will kick off the new monthly subspecialty education series with a virtual session on September 9, 2025, focused on using OCT imaging and perimetry to track glaucoma progression.

Surgical tools improve Schlemm canal access and enable earlier glaucoma care.

The study will be evaluating the safety, tolerability, and efficacy of QLS-111 in adult patients with normal tension glaucoma.

NCX 470 met the primary endpoint of non-inferiority in lowering intraocular pressure (IOP) from baseline compared to the standard of care, latanoprost 0.005%.

Steel and the Glaucoma Research Foundation have a relationship spanning over a decade.

The ADAPT study will evaluate the safety and effectiveness of the Calibreye surgical system in up to 70 patients with refractory glaucoma.

New research findings reveal that increased physical activity significantly slows visual field loss in patients with glaucoma, highlighting exercise as a potential protective factor.

PA5108 is a rod-shaped, biodegradable microimplant designed to significantly reduce IOP in patients with primary open-angle glaucoma consistently over 6 months.

Nicox and Kowa entered into an agreemen in February 2024, in which Kowa was granted exclusive Japanese rights to develop and commercialize NCX 470.

Eyetronic is a noninvasive treatment for glaucoma that provides external neural stimulation to the optic nerve of patients.

The law will work to remove outdated restrictions on medications and allow some in-office procedures and will take effect in August.

Under the terms of the agreement, Kowa receives exclusive rights to develop and commercialize NCX 470 in the US and all other territories of the world excluding Japan, China, Korea, and Southeast Asia.

Alcon’s Voyager is a fully automated, noncontact treatment approach that delivers 120 laser pulses through the limbus of the trabecular meshwork.

Ophthalmologists discuss the most impactful advancements reshaping patient care over five decades.

In honor of Ophthalmology Times’ 50th anniversary, anterior segment surgeons attending ASCRS 2025 weigh in on the innovations that defined modern ophthalmology.

Both 6-month trials were randomized, controlled studies that evaluated PER-001 delivered in a slow-release, dissolvable implant injected intravitreally every 6 months.

All 696 patients in the trial have completed their treatment and follow-up visits.

Perfuse Therapeutics is conducting trials for the treatment for glaucoma and diabetic retinopathy, aiming to restore vision and combat global blindness.

From Nobel laureates to AI-driven research, the Wilmer Eye Institute honors a century of transforming vision science and care.

Qlaris Bio to showcase promising data on QLS-111, a novel glaucoma treatment, at the 2025 World Glaucoma Congress, highlighting its efficacy and safety.

Perfuse Therapeutics reveals promising Phase 2 trial results for PER-001, a potential treatment for glaucoma and diabetic retinopathy.

Funding will support the continued clinical advancement of its lead ocular implant candidate, PA5108, for the reduction of IOP in patients with ocular hypertension and glaucoma.

EssilorLuxottica and MidEuropa recently entered into an agreement that will allow EssilorLuxottica to acquire Optegra, building upon its med-tech strategy.

The novel preservative-free eye drop therapy for glaucoma aims to improve IOP control and patient adherence with a fixed-dose combination.